A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
Completed · Phase 2 · Has a placebo group
Conditions studied: Obesity
In brief
The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo). Which treatment participants get is decided by chance. Participants will get 2 injections per week, on the same day. Participants will have to take the study medicine by use of a pre-filled pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show participants how. The study will last for about 26 weeks. Participants will have 17 visits at the clinic with the study doctor. At 4 of the clinic visits participants cannot eat and drink (water is allowed until 2 hours prior to the visit) for 8 hours before the visit.Women: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period. Women who are able to become pregnant can participate if they agree to use contraception during the study.
Key facts
- Study ID
- NCT04969939
- Run by
- Novo Nordisk A/S
- People needed
- 120
- Starts
- 2021-07-15
- Expected to finish
- 2023-01-30
- Last updated by the study team
- 2026-01-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
- Male or female, age above or equal to 18 years at the time of signing informed consent.
- BMI 30.0-45.0 kg/m\^2 (both inclusive) at the screening visit.
You may not qualify if…
- HbA1c greater than or equal to 48 mmol/mol (6.5%) as measured by a central laboratory at screening.
- History of type 1 or type 2 diabetes mellitus.
- Treatment with glucose-lowering agent(s) within 90 days before screening.
Where it is running
- Univ of Alabama Birmingham — Birmingham, Alabama, United States
- Anaheim Clinical Trials, LLC — Anaheim, California, United States
- Profil Institute For Clinical Research Inc — Chula Vista, California, United States
- Velocity Clin Res Los Angeles — Los Angeles, California, United States
- Diablo Clinical Research, Inc. — Walnut Creek, California, United States
- Jacksonville Ctr For Clin Res — Jacksonville, Florida, United States
- Endo Res Solutions Inc — Roswell, Georgia, United States
- East West Med Res Inst — Honolulu, Hawaii, United States
- Evanston Premier Hlthcr Res — Skokie, Illinois, United States
- Altasciences Clinical Kansas, Inc. — Overland Park, Kansas, United States
- L-MARC Research Center — Louisville, Kentucky, United States
- AMC Community Endocrinology — Albany, New York, United States
- NYC Research, Inc. — New York, New York, United States
- PharmQuest Life Sciences LLC — Greensboro, North Carolina, United States
- Accellacare — Wilmington, North Carolina, United States
- Medical Uni of SC Charleston — Charleston, South Carolina, United States
- Coastal Carolina Res Ctr. — North Charleston, South Carolina, United States
- Texas Diabetes & Endocrinology, P.A._Austin — Austin, Texas, United States
- Soltero Cardiovascular Research Center — Dallas, Texas, United States
- Texas Diabetes & Endocrinology, P.A._Austin — Round Rock, Texas, United States
- Chrysalis Clinical Research — St. George, Utah, United States
- Washington Cntr Weight Mgmt — Arlington, Virginia, United States
- Health Res of Hampton Roads — Newport News, Virginia, United States
- National Clin Res Inc. — Richmond, Virginia, United States
- Selma Medical Associates — Winchester, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.